Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Podcasts
PR24 redetermination: what the CMA’s decision means for UK households and water regulation
In this special edition of Top of the Agenda, we’re diving into the UK water sector to explore the Competition and Markets Authority’s (CMA) final determinations: the PR 24 Redetermination process. In England and Wales, the amount consumers pay for their water is regulated by the Office of Water Regulation… Read More
The reality gap: testing AI from compliance to enforcement
Companies and regulators often operate with distinct immediate objectives, e.g. profit maximisation versus consumer protection. Yet, as artificial intelligence (AI) increasingly permeates the economy, both sides face a shared challenge: navigating the opacity of complex algorithms. For companies, the primary imperative is risk management. A newly deployed algorithm that inadvertently… Read More